uniQure (NASDAQ:QURE) Releases Quarterly Earnings Results, Misses Expectations By $0.40 EPS

uniQure (NASDAQ:QURE) posted its earnings results on Wednesday. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.40), FiscalAI reports. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.50 million. During the same period in the previous year, the company posted ($0.69) EPS.

Here are the key takeaways from uniQure’s conference call:

• AMT-130 remains on track for a U.S. BLA submission in the third quarter under the FDA’s Accelerated Approval pathway, with three-year Phase I/II data accepted as the primary basis. A U.K. submission to the MHRA is also planned for the third quarter.
• The FDA indicated that a confirmatory study may use a randomized standard-of-care control rather than a sham procedure, potentially simplifying execution. uniQure expects to align on the design and begin a global study promptly, with Total Functional Capacity at 36 months under consideration as the primary endpoint.
• uniQure expects to present four-year AMT-130 data in September, including safety, tolerability, functional outcomes, natural-history comparisons and CSF neurofilament light data. Management is in a quiet period and declined to provide additional commentary on the results ahead of the readout.
• Early AMT-260 epilepsy data showed seizure reductions of 79% to 100% below baseline in three of six low-dose patients, but outcomes varied widely among the remaining participants; higher-dose enrollment is nearly complete. AMT-191 produced dose-dependent enzyme activity increases in all 11 patients, although two grade 3 liver-enzyme events paused further mid- and high-dose dosing pending FDA agreement on monitoring.
• Cash, cash equivalents and investments totaled $810.3 million at quarter-end, up from $622.5 million at year-end 2025, and management expects the balance sheet to fund operations, the confirmatory trial, potential AMT-130 launches and ongoing development into 2030.

uniQure Stock Up 0.8%

Shares of QURE traded up $0.34 during midday trading on Thursday, hitting $40.41. The company had a trading volume of 798,928 shares, compared to its average volume of 2,571,616. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50. The firm has a market capitalization of $2.55 billion, a P/E ratio of -11.58 and a beta of 0.90. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40. The company’s 50-day simple moving average is $36.75 and its 200-day simple moving average is $26.01.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Wells Fargo raised its price target from $60 to $75 and initiated or reaffirmed an “overweight” rating, implying substantial upside from recent trading levels. The upgrade reflects growing confidence in uniQure’s Huntington’s disease gene-therapy opportunity. Benzinga report
• Positive Sentiment: uniQure said U.S. and U.K. regulatory submissions for AMT-130 remain on track for the third quarter of 2026. The company also expects topline four-year clinical data in September, creating near-term catalysts for the stock. An advisory committee, or AdCom, is also expected to review the Huntington’s gene therapy. AMT-130 BLA update AdCom report
• Positive Sentiment: The company reported $810.3 million in cash, cash equivalents and current investments following a $259 million follow-on offering. Management expects the cash runway to fund operations into 2030, including a potential AMT-130 commercial launch and additional pipeline development. Early AMT-260 data also showed potentially meaningful seizure reductions in three of six low-dose patients, although the dataset remains small. uniQure second-quarter results
• Neutral Sentiment: Second-quarter revenue rose to approximately $5.8 million from $5.3 million a year earlier, but the company remains heavily dependent on future clinical and regulatory success rather than current commercial revenue. Q2 2026 earnings report
• Negative Sentiment: uniQure reported a $1.22 per-share loss, wider than the $0.82 consensus estimate and worse than the $0.69 loss recorded a year earlier. Net loss expanded to $81.1 million, highlighting continued high cash consumption ahead of potential approvals. Q2 loss report
• Negative Sentiment: Reported insider activity showed selling without disclosed purchases over the past six months, a potential cautionary signal for investors, although these transactions may reflect compensation or planned sales rather than a change in business outlook.

Insider Activity

In other uniQure news, Director Jack Kaye sold 21,167 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the sale, the director directly owned 25,996 shares of the company’s stock, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the sale, the director directly owned 43,254 shares in the company, valued at approximately $1,949,025.24. This represents a 21.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 433,229 shares of company stock valued at $17,944,799 over the last three months. 4.65% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several large investors have recently bought and sold shares of QURE. Woodline Partners LP raised its stake in uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after buying an additional 35,175 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of uniQure during the 2nd quarter worth about $497,000. Marshall Wace LLP increased its holdings in shares of uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of uniQure in the 2nd quarter valued at about $540,000. Finally, Ameriprise Financial Inc. raised its position in shares of uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on QURE shares. Mizuho boosted their price target on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Chardan Capital raised their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Royal Bank Of Canada lifted their price objective on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, June 18th. HC Wainwright upped their target price on shares of uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research note on Wednesday, June 17th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $65.00.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.